kent pharmaceuticals limited
kent pharmaceuticals limited Company Information
Company Number
03371228
Website
www.kentpharm.co.ukRegistered Address
2nd floor, connect 38, 1 dover place, ashford, kent, TN23 1FB
Industry
Manufacture of basic pharmaceutical products
Telephone
08454375565
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
kent pharma holdings limited 100%
kent pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of KENT PHARMACEUTICALS LIMITED at £0 based on a Turnover of £0 and 1.14x industry multiple (adjusted for size and gross margin).
kent pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of KENT PHARMACEUTICALS LIMITED at £0 based on an EBITDA of £-176k and a 5.36x industry multiple (adjusted for size and gross margin).
kent pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of KENT PHARMACEUTICALS LIMITED at £0 based on Net Assets of £-2m and 2.18x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Kent Pharmaceuticals Limited Overview
Kent Pharmaceuticals Limited is a live company located in ashford, TN23 1FB with a Companies House number of 03371228. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in May 1997, it's largest shareholder is kent pharma holdings limited with a 100% stake. Kent Pharmaceuticals Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Kent Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Kent Pharmaceuticals Limited a 0.5 rating. We use a traffic light system to show it exceeds the industry average on 0 measures and has 3 areas for improvement. Company Health Check FAQs
0 Strong
1 Regular
3 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Kent Pharmaceuticals Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Kent Pharmaceuticals Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Kent Pharmaceuticals Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Kent Pharmaceuticals Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (136)
- Kent Pharmaceuticals Limited
- - Industry AVG
Pay Structure
on an average salary of £53.3k, the company has an equivalent pay structure (£53.3k)
- Kent Pharmaceuticals Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Kent Pharmaceuticals Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Kent Pharmaceuticals Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Kent Pharmaceuticals Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Kent Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 1 weeks, this is less cash available to meet short term requirements (12 weeks)
- - Kent Pharmaceuticals Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 1930.8%, this is a higher level of debt than the average (46.2%)
- - Kent Pharmaceuticals Limited
- - Industry AVG
KENT PHARMACEUTICALS LIMITED financials
Kent Pharmaceuticals Limited's latest turnover from March 2023 is 0 and the company has net assets of -£2 million. According to their latest financial statements, we estimate that Kent Pharmaceuticals Limited has 1 employee and maintains cash reserves of £75 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Aug 2012 | Aug 2011 | Aug 2010 | Aug 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0 | 0 | 0 | 0 | 39,251,000 | 59,822,000 | 69,985,000 | 69,875,000 | 66,572,000 | 32,473,000 | 66,732,000 | 67,689,041 | 53,237,107 | 37,160,352 | |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Cost Of Sales | 28,945,000 | 45,173,000 | 49,120,000 | 50,228,000 | 48,987,000 | 27,263,000 | 53,955,000 | 54,859,055 | 42,012,373 | 28,619,255 | |||||
| Gross Profit | 10,306,000 | 14,649,000 | 20,865,000 | 19,647,000 | 17,585,000 | 5,210,000 | 12,777,000 | 12,829,986 | 11,224,734 | 8,541,097 | |||||
| Admin Expenses | 17,855,000 | 12,597,000 | 18,543,000 | 17,434,000 | 11,021,545 | 8,122,301 | 5,830,256 | ||||||||
| Operating Profit | -186,000 | -53,000 | -43,000 | -12,000 | -7,549,000 | 2,052,000 | 2,322,000 | 2,213,000 | 1,808,441 | 3,102,433 | 2,710,841 | ||||
| Interest Payable | 0 | 0 | 0 | 45,000 | 374,000 | 482,000 | 685,000 | 0 | 12,000 | 52,000 | 136,000 | 148,972 | 23,330 | 42 | |
| Interest Receivable | 0 | 0 | 0 | 0 | 4,000 | 3,000 | 12,000 | 32,000 | 16,000 | 7,000 | 0 | 199 | 2,813 | 26,710 | |
| Pre-Tax Profit | -186,000 | -53,000 | -43,000 | -57,000 | -7,919,000 | 1,573,000 | 1,649,000 | 2,245,000 | 1,581,000 | -5,920,000 | 2,263,000 | 1,659,668 | 281,916 | 2,737,509 | |
| Tax | 0 | 0 | 1,000 | 0 | -393,000 | -285,000 | 90,000 | -496,000 | -293,000 | 297,000 | -627,000 | -452,653 | -132,676 | -112,025 | |
| Profit After Tax | -186,000 | -53,000 | -42,000 | -57,000 | -8,312,000 | 1,288,000 | 1,739,000 | 1,749,000 | 1,288,000 | -5,623,000 | 1,636,000 | 1,207,015 | 149,240 | 2,625,484 | |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Retained Profit | -186,000 | -53,000 | -42,000 | -57,000 | -8,312,000 | 1,288,000 | 1,739,000 | 1,749,000 | 1,288,000 | -5,623,000 | 1,636,000 | 1,207,015 | 149,240 | 2,625,484 | |
| Employee Costs | 1,822,000 | 2,918,000 | 4,546,000 | 4,658,000 | 4,683,000 | 2,712,000 | 7,213,000 | 7,876,908 | 5,539,401 | 3,673,657 | |||||
| Number Of Employees | 43 | 68 | 148 | 150 | 156 | 158 | 168 | 161 | 138 | 133 | |||||
| EBITDA* | -176,000 | -43,000 | -33,000 | -12,000 | -6,922,000 | 2,858,000 | 4,136,000 | 3,798,000 | 2,043,417 | 3,310,207 | 2,776,891 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Aug 2012 | Aug 2011 | Aug 2010 | Aug 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 443,000 | 598,000 | 765,000 | 875,000 | 843,000 | 1,331,000 | 1,404,862 | 1,723,266 | 291,613 |
| Intangible Assets | 32,000 | 0 | 10,000 | 20,000 | 0 | 0 | 5,243,000 | 5,790,000 | 6,624,000 | 7,757,000 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 8,849,000 | 8,849,000 | 8,226,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 32,000 | 0 | 10,000 | 20,000 | 0 | 0 | 14,535,000 | 15,237,000 | 15,615,000 | 8,632,000 | 843,000 | 1,331,000 | 1,404,862 | 1,723,266 | 291,613 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 13,168,000 | 12,092,000 | 13,266,000 | 11,904,000 | 7,504,000 | 10,207,000 | 13,724,724 | 9,784,084 | 4,640,390 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 10,600,000 | 10,045,000 | 11,421,000 | 10,510,000 | 9,540,000 | 10,933,000 | 15,308,706 | 9,044,158 | 7,295,373 |
| Group Debtors | 0 | 0 | 9,000 | 0 | 0 | 13,743,000 | 1,784,000 | 3,049,000 | 25,000 | 244,000 | 219,000 | 432,000 | 774,376 | 440,032 | 364,493 |
| Misc Debtors | 0 | 2,000 | 0 | 46,000 | 0 | 795,000 | 788,000 | 583,000 | 919,000 | 830,000 | 1,041,000 | 885,000 | 485,075 | 646,503 | 456,091 |
| Cash | 75,000 | 135,000 | 39,000 | 36,000 | 0 | 441,000 | 1,445,000 | 4,665,000 | 5,529,000 | 11,026,000 | 2,923,000 | 334,000 | 465,745 | 68,562 | 4,310,898 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 352 | 0 | 0 |
| total current assets | 75,000 | 137,000 | 48,000 | 82,000 | 0 | 14,979,000 | 27,785,000 | 30,434,000 | 31,160,000 | 34,514,000 | 21,227,000 | 22,791,000 | 30,758,978 | 19,983,339 | 17,067,245 |
| total assets | 107,000 | 137,000 | 58,000 | 102,000 | 0 | 14,979,000 | 42,320,000 | 45,671,000 | 46,775,000 | 43,146,000 | 22,070,000 | 24,122,000 | 32,163,840 | 21,706,605 | 17,358,858 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,707,000 | 1,501,000 | 1,373,826 | 1,718,274 | 1,057,211 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 150,000 | 0 | 0 |
| Trade Creditors | 1,000 | 0 | 0 | 0 | 0 | 0 | 6,568,000 | 7,169,000 | 8,911,000 | 7,562,000 | 3,104,000 | 3,615,000 | 2,994,026 | 4,758,387 | 2,960,404 |
| Group/Directors Accounts | 2,061,000 | 1,908,000 | 1,778,000 | 1,778,000 | 0 | 16,078,000 | 16,403,000 | 20,925,000 | 26,677,000 | 24,237,000 | 6,051,000 | 6,199,000 | 9,489,097 | 5,315,181 | 5,117,904 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,558,132 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 4,000 | 2,000 | 0 | 2,000 | 0 | 270,000 | 5,227,000 | 5,644,000 | 5,271,000 | 5,019,000 | 5,114,000 | 5,536,000 | 7,458,145 | 5,006,164 | 4,713,980 |
| total current liabilities | 2,066,000 | 1,910,000 | 1,778,000 | 1,780,000 | 0 | 16,348,000 | 28,198,000 | 33,738,000 | 40,859,000 | 36,818,000 | 15,976,000 | 16,851,000 | 26,023,226 | 16,798,006 | 13,849,499 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 500,000 | 650,000 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 7,145,000 | 5,961,000 | 2,000,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 625,000 | 1,250,000 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 34,000 | 317,000 | 0 | 4,161,000 | 5,215,000 | 269,000 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 7,179,000 | 6,278,000 | 2,000,000 | 4,161,000 | 5,215,000 | 769,000 | 1,275,000 | 1,250,000 | 0 |
| total liabilities | 2,066,000 | 1,910,000 | 1,778,000 | 1,780,000 | 0 | 16,348,000 | 35,377,000 | 40,016,000 | 42,859,000 | 40,979,000 | 21,191,000 | 17,620,000 | 27,298,226 | 18,048,006 | 13,849,499 |
| net assets | -1,959,000 | -1,773,000 | -1,720,000 | -1,678,000 | 0 | -1,369,000 | 6,943,000 | 5,655,000 | 3,916,000 | 2,167,000 | 879,000 | 6,502,000 | 4,865,614 | 3,658,599 | 3,509,359 |
| total shareholders funds | -1,959,000 | -1,773,000 | -1,720,000 | -1,678,000 | 0 | -1,369,000 | 6,943,000 | 5,655,000 | 3,916,000 | 2,167,000 | 879,000 | 6,502,000 | 4,865,614 | 3,658,599 | 3,509,359 |
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Aug 2012 | Aug 2011 | Aug 2010 | Aug 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -186,000 | -53,000 | -43,000 | -12,000 | -7,549,000 | 2,052,000 | 2,322,000 | 2,213,000 | 1,808,441 | 3,102,433 | 2,710,841 | ||||
| Depreciation | 0 | 0 | 0 | 0 | 101,000 | 205,000 | 210,000 | 249,000 | 208,000 | 141,000 | 266,000 | 234,976 | 207,774 | 66,050 | |
| Amortisation | 10,000 | 10,000 | 10,000 | 0 | 526,000 | 601,000 | 1,604,000 | 1,336,000 | 1,279,000 | 0 | 0 | 0 | 0 | 0 | |
| Tax | 0 | 0 | 1,000 | 0 | -393,000 | -285,000 | 90,000 | -496,000 | -293,000 | 297,000 | -627,000 | -452,653 | -132,676 | -112,025 | |
| Stock | 0 | 0 | 0 | 0 | 0 | -13,168,000 | 1,076,000 | -1,174,000 | 1,362,000 | 4,400,000 | -2,703,000 | -3,517,724 | 3,940,640 | 5,143,694 | 4,640,390 |
| Debtors | -2,000 | -7,000 | -37,000 | 46,000 | -14,538,000 | 1,366,000 | -505,000 | 1,312,000 | 781,000 | 784,000 | -1,450,000 | -4,318,157 | 6,437,464 | 2,014,736 | 8,115,957 |
| Creditors | 1,000 | 0 | 0 | 0 | 0 | -6,568,000 | -601,000 | -1,742,000 | 1,349,000 | 4,458,000 | -511,000 | 620,974 | -1,764,361 | 1,797,983 | 2,960,404 |
| Accruals and Deferred Income | 2,000 | 2,000 | -2,000 | 2,000 | -270,000 | -12,102,000 | 767,000 | 4,334,000 | 2,252,000 | -95,000 | -422,000 | -1,922,145 | 2,451,981 | 292,184 | 4,713,980 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | -34,000 | -283,000 | 317,000 | -4,161,000 | -1,054,000 | 4,946,000 | 269,000 | 0 | 0 | 0 |
| Cash flow from operations | -171,000 | -34,000 | 3,000 | -56,000 | -14,217,000 | 1,885,000 | 6,997,000 | 599,000 | -8,099,720 | -1,890,732 | -2,417,097 | ||||
| Investing Activities | |||||||||||||||
| capital expenditure | 5,695 | -1,700,879 | 10,750 | ||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | -8,849,000 | 0 | 623,000 | 8,226,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | 5,695 | -1,700,879 | 10,750 | ||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -150,000 | 150,000 | 0 | 0 |
| Group/Directors Accounts | 153,000 | 130,000 | 0 | 1,778,000 | -16,078,000 | -325,000 | -4,522,000 | -5,752,000 | 2,440,000 | 18,186,000 | -148,000 | -3,290,097 | 4,173,916 | 197,277 | 5,117,904 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4,558,132 | 4,558,132 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -500,000 | -150,000 | 650,000 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -625,000 | -625,000 | 1,250,000 | 0 |
| share issue | |||||||||||||||
| interest | 0 | 0 | 0 | -45,000 | -370,000 | -479,000 | -673,000 | 32,000 | 4,000 | -45,000 | -136,000 | -148,773 | -20,517 | 26,668 | |
| cash flow from financing | 153,000 | 130,000 | 0 | 112,000 | -695,000 | -5,001,000 | -6,425,000 | 2,472,000 | 18,190,000 | -693,000 | -8,908,843 | 8,758,275 | 1,426,760 | 6,028,447 | |
| cash and cash equivalents | |||||||||||||||
| cash | -60,000 | 96,000 | 3,000 | 36,000 | -441,000 | -1,004,000 | -3,220,000 | -864,000 | -5,497,000 | 8,103,000 | 2,589,000 | -131,745 | 397,183 | -4,242,336 | 4,310,898 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1,707,000 | 206,000 | 127,174 | -344,448 | 661,063 | 1,057,211 |
| change in cash | -60,000 | 96,000 | 3,000 | 36,000 | -441,000 | -1,004,000 | -3,220,000 | -864,000 | -5,497,000 | 9,810,000 | 2,383,000 | -258,919 | 741,631 | -4,903,399 | 3,253,687 |
kent pharmaceuticals limited Credit Report and Business Information
Kent Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for kent pharmaceuticals limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
kent pharmaceuticals limited Ownership
KENT PHARMACEUTICALS LIMITED group structure
Kent Pharmaceuticals Limited has 1 subsidiary company.
Ultimate parent company
2 parents
KENT PHARMACEUTICALS LIMITED
03371228
1 subsidiary
kent pharmaceuticals limited directors
Kent Pharmaceuticals Limited currently has 4 directors. The longest serving directors include Mr David Wright (Sep 2019) and Mr David Wright (Sep 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr David Wright | England | 60 years | Sep 2019 | - | Director |
| Mr David Wright | England | 60 years | Sep 2019 | - | Director |
| Mr David Wright | England | 60 years | Sep 2019 | - | Director |
| Mr Kevin James | United Kingdom | 69 years | Mar 2022 | - | Director |
P&L
March 2023turnover
0
0%
operating profit
-186k
+251%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
-2m
+0.1%
total assets
107k
-0.22%
cash
75k
-0.44%
net assets
Total assets minus all liabilities
Similar Companies
kent pharmaceuticals limited company details
company number
03371228
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
May 1997
age
27
accounts
Audit Exemption Subsidiary
ultimate parent company
previous names
premier pharmaceuticals limited (September 2008)
vaughan data limited (September 1997)
incorporated
UK
address
2nd floor, connect 38, 1 dover place, ashford, kent, TN23 1FB
last accounts submitted
March 2023
kent pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 4 charges/mortgages relating to kent pharmaceuticals limited. Currently there are 2 open charges and 2 have been satisfied in the past.
kent pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
